EnteroMedics Inc., based in Roseville, Minnesota, said Monday that the Food and Drug Administration has approved a new clinical trial for its Maestro anti-obesity device that uses electricity to suppress hunger.
The news represents a major victory for EnteroMedics whose previous study ended in failure. Last October, initial results from the EMPOWER studies of more than 400 patients showed people who used the Maestro device lost just as much weight as patients implanted with the dummy device.
Market Trends to Watch for Health Systems and Their Specialty Pharmacies
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
In a previous interview, CEO Mark Knudson said wires from the sham device connected to the nerve released low-intensity energy whenever the company performed a safety check on the device. As a result, the Maestro device delivered 10,000 times more electricity to the therapy group but did not perform any better than the control group’s dummy device.
Since January, the company has been negotiating with the FDA on a study through the agency’s Investigational Device Exemption program.
The new 12 month study, dubbed ReCharge, will enroll 234 morbidly obese people who will randomly be implanted with Maestro or a sham device. This time, the dummy device will have no wires connected to the nerve. Patients will also use an updated Maestro device in which the battery pack will be worn around the belt instead of an implant.
The company hopes patients with Maestro will lose 20 percent more weight than people implanted with the dummy device. The trial will begin the second half of 2011.
3D Medical Animation Services: A Revolution in Healthcare Education and Marketing
3D medical animation services have emerged as a groundbreaking tool in the healthcare industry, revolutionizing the way medical concepts are taught, understood, and marketed.